Phenothiazines inhibit SARS-CoV-2 cell entry via a blockade of spike protein binding to neuropilin-1
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phenothiazines inhibit SARS-CoV-2 cell entry via a blockade of spike protein binding to neuropilin-1
Authors
Keywords
-
Journal
ANTIVIRAL RESEARCH
Volume 209, Issue -, Pages 105481
Publisher
Elsevier BV
Online
2022-12-06
DOI
10.1016/j.antiviral.2022.105481
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection
- (2022) Naoko Iwata-Yoshikawa et al. Science Advances
- Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen
- (2022) Zaid Taha et al. MOLECULAR THERAPY
- Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways
- (2022) Naoko Iwata-Yoshikawa et al. Nature Communications
- No higher infectivity but immune escape of SARS-CoV-2 501Y.V2 variants
- (2021) Qianqian Li et al. CELL
- SARS-CoV-2 and SARS-CoV spike-mediated cell-cell fusion differ in the requirements for receptor expression and proteolytic activation
- (2021) Bojan F. Hörnich et al. JOURNAL OF VIROLOGY
- Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice
- (2021) Kun Huang et al. EBioMedicine
- Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs
- (2021) Robert T. Schooley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- TMPRSS2 expression dictates the entry route used by SARS‐CoV‐2 to infect host cells
- (2021) Jana Koch et al. EMBO JOURNAL
- Characterization of a new SARS-CoV-2 variant that emerged in Brazil
- (2021) Masaki Imai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2
- (2021) Tia A. Tummino et al. SCIENCE
- A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry
- (2021) Yanwen Chen et al. Nature Communications
- SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice
- (2021) Emma S. Winkler et al. JOURNAL OF VIROLOGY
- A new coronavirus associated with human respiratory disease in China
- (2020) Fan Wu et al. NATURE
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
- (2020) Markus Hoffmann et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2
- (2020) Ren-Di Jiang et al. CELL
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
- (2020) Linlin Bao et al. NATURE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
- (2020) Xiuyuan Ou et al. Nature Communications
- Filovirus Antiviral Activity of Cationic Amphiphilic Drugs Is Associated with Lipophilicity and Ability To Induce Phospholipidosis
- (2020) Antonia P. Gunesch et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
- (2020) Bette Korber et al. CELL
- Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
- (2020) Laura Riva et al. NATURE
- Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy
- (2020) Hongjing Gu et al. SCIENCE
- A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice
- (2020) Sarah R. Leist et al. CELL
- Neuropilin-1 is a host factor for SARS-CoV-2 infection
- (2020) James L. Daly et al. SCIENCE
- Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity
- (2020) Ludovico Cantuti-Castelvetri et al. SCIENCE
- Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models
- (2020) Gan Wang et al. CELL RESEARCH
- FDA Approval of Remdesivir — A Step in the Right Direction
- (2020) Daniel Rubin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction
- (2020) Wenyu Fu et al. Protein & Cell
- Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro
- (2020) Jiayu Lu et al. LIFE SCIENCES
- Baricitinib: A Review in Rheumatoid Arthritis
- (2018) Zaina T. Al-Salama et al. DRUGS
- Antiviral activity of cationic amphiphilic drugs
- (2017) Cristiano Salata et al. Expert Review of Anti-Infective Therapy
- Cationic amphiphilic drugs enhance entry of lentiviral particles pseudotyped with rabies virus glycoprotein into non-neuronal cells
- (2015) Anneke Klintworth et al. ANTIVIRAL RESEARCH
- Phenothiazine-Derived Antipsychotic Drugs Inhibit Dynamin and Clathrin-Mediated Endocytosis
- (2015) James A. Daniel et al. TRAFFIC
- Chemical structure of phenothiazines and their biological activity
- (2014) Agata Jaszczyszyn et al. Pharmacological Reports
- Structural Basis for Selective Vascular Endothelial Growth Factor-A (VEGF-A) Binding to Neuropilin-1
- (2012) Matthew W. Parker et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mechanism of Selective VEGF-A Binding by Neuropilin-1 Reveals a Basis for Specific Ligand Inhibition
- (2012) Matthew W. Parker et al. PLoS One
- Recent progress in biological activities of synthesized phenothiazines
- (2011) Krystian Pluta et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started